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This paper describes a heuristic Bayesian method for computing probability 
distributions from experimental data, based upon the normal distribution form of 
the influence diagram. An example illustrates its use in medical technology 
assessment. This approach facilitates the integration of results from different 
studies, and permits a medical expert to make proper assessments without 
considerable statistical training. 
There has been extensive research on the construction and manipulation of 
expert systems using probabilities as a measure for uncertainty. These systems are 
capable of recognizing considerable dependence and of learning from unreliable 
observations. These models are inherentlysubjective, and the probabilities on which 
they are based are the beliefs of somedecision maker. As the evidence accumulates, 
the decision maker has less uncertainty about the states of the world and he can make a 
better decision. This framework has proven successful for learning about a given 
individual or situation. For example, a physician could incorporate her observations from 
tests and examinations into a distribution which describes her beliefs about a patient's 
underlying disorder. The subjectivity of the probabilities is a necessary "evil," since the 
responsibility for the decision clearly lies with the physician. In exchange, she has a 
powerful framework at her disposal. 
In this paper, our goal is to develop the prior probabilities for the population 
parameters on which the individual model is based. We use the results of scientific 
experiments to learn about an entire class of situations or individuals, rather than just one. 
For example, we might derive the probability distribution over health outcomes for a class 
of patients undergoing treatment for a given health problem. As in the paradigm above, 
we revise our initial opinions on the basis of observations. There is still a need for 
subjective judgment, in weighing and sifting the experimental evidence. However, it is 
important that our results be defensible, since the probabilities {and conclusions) will be 
used by other decision makers in the provision of patient care and the selection of 
treatments. Therefore, our goal is to incorporate all relevant experimental data in our 
analysis, and to use it in an appropriate manner. 
tvisiting CHPRE from the Department of Engineering-Economic Systems, Stanford University. 
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There are several technical problems which must be overcome in our work. First, 
there are often a large number of dependent variables, the population parameters. 
Second, since most of these variables are probabilities, they are necessarily continuous­
valued. Finally, it takes specialized skills and expertise to properly interpret and integrate 
the experimental data so that it can be prepared for analysis. Therefore, we would like to 
have a methodology that requires minimal additional statistical knowledge to perform that 
analysis. 
We have developed a methodology for solving this problem in order to analyze 
alternative medical technologies (Eddy, 1986). It has been used to solve many 
problems, including an analysis of the efficacy of tissue-type Plasminogen Activator (t­
PA) in the treatment of heart attacks (Eddy, 1987). This analysis was performed using a 
prototype system (Hasselblad et al, 1986) written in APL on the PC. The system 
maintains probability distributions for each of the population parameters and manipulates 
them through one-dimensional numerical integration. 
In this paper, we develop a heuristic approach to this problem, based on a 
multivariate normal distribution, represented as a normal influence diagram (Kenley, 
1986, and Shachter and Kenley, 1987). We illustrate the approach with the example of t­
PA. In our preliminary trials, this heuristic approach has performed surprisingly well. It is 
much faster and simpler to use than the numerical integration approach, without much 
loss in accuracy. Furthermore since dependencies are easy to address, we did not need 
to make some simplifying assumptions that were made in the earlier analysis of t-PA, and 
the results of our analysis are in the form of a joint distribution for all of the variables in the 
model. 
Recent news illustrates the need for an accepted approach to address these 
issues. The Food and Drug Administration advisory panel recommended against the 
approval of t-PA on May 28, 1987 (Wall Street Journal, 1987). Since no studies have 
been performed on the long-term survival of patients treated with t-PA, one of the panel 
members said "I'd like to believe that clot (dissolution) leads to improved survival, but 
based on the numbers we've seen today, I don't think we can conclude that." The 
methodology we present provides the mechanism for reaching such a conclusion from 
the evidence available to the panel. 
Problem Setting 
Medical technology assessments are used to compare alternative therapies for a 
patients condition based on experimental data. A full analysis considers not just the 
relative efficacy of different treatments, but also their costs and use of scarce resources. 
The demand for technology assessments has grown along with escalating health care 
costs and the efforts to control those costs. 
To carry out an assessment properly requires extensive medical and quantitative 
230 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
skills. The data are often incomplete, inconsistent, or noncomparable. The measures of 
performance might differ from one study to another. Often studies are performed on 
patients with different characteristics, or there might be variations on the treatments and 
dosages offered. There are often variations in the manner by which patients enter or 
leave the study group. All of these complications demand an appreciation of both the 
medical and statistical implications, and can involve a fair amount of subject "adjustment," 
to clean up the data for analysis. 
As a specific example, we will be considering the efficacy of three treatments for a 
heart attack: conventional care (CC), and two thrombolytic agents (TA),  intravenous 
streptokinase (IVSK) and t-PA. Our goal is to compute the difference in the probability of 
one-year mortality given t-PA versus CC. Some of the relevant studies followed patients 
for a full year after treatment, but others only measure whether reperfusion occurs soon 
after treatment. In particular, there are no direct data on one-year mortality after t-PA 
treatment. The influence diagram for a physician treating a patient is given in Figure 1. 
There is a decision on the Treatment to administer, and subsequent events, 
Reperfusion, and one-year Mortality. We assume that the probability of Reperfusion 
depends on the choice of Treatment, and that Mortality depends on both Treatment and 
Reperfusion. 
Treatment 
Decision 
Figure 1. Influence Diagram for the Treatment of a Patient with a Heart Attack. 
We have been working for several years to develop a technology assessment 
processing system for the PC (Eddy, 1986, Hasselblad et al, 1986). The system stores a 
discrete, but detailed, distribution for each variable (population parameter) in an 
assessment. It manipulates, adjusts, combines, and displays these distributions. It is 
menu-driven and relieves the user of the computational burden in performing analyses. 
This system has been used to perform many assessments, including an analysis of the 
relative efficacy of t-PA versus conventional care (Eddy, 1987). 
There are several weaknesses of the PC system that this new line of research is 
designed to address. The system in its current design is a powerful calculator, but it has 
little appreciation of the semantics of the problem. As a result, the user must supply a 
series of computation commands to perform an analysis. If one of the inputs is revised, 
the same series of commands must be repeated. Also, there is no way to check the 
semantic validity of the operations. There are serious and complex issues of evidertce 
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evaluation and consolidation, which the user of the system must resolve without help 
from the system. Finally, the system thinks in terms of one-dimensional uncertainty. It 
cannot explicitly represent a general joint distribution for two or more dependent 
variables. 
Normal Influence Diagram 
The key to our new approach is the multivariate normal version of the influence 
diagram {Howard and Matheson, 1981 ). All of the manipulations needed to solve 
problems in a discrete influence diagram {Shachter, 1986) can be easily performed on a 
Gaussian model as well (Kenley, 1986, Shachter and Kenley, 1987). In fact, this is the 
simplest possible influence diagram which recognizes dependent, continuous random 
variables. It assumes that every variable is a linear function of other variables in the model 
plus some independent, normally-distributed "noise." These assumptions of linearity 
and normality simplify the representation, assessment, and manipulation of these 
models. Because the size of the problem grows only with the square of the number of 
variables, this is a logical model for a problem with many dependent, continuous 
variables. 
The influence diagram representation of a multivariate normal requires a minimum 
number of parameters to be assessed. For every variable Xj in the model with 
conditioning variables C(j), we must assess its conditional mean, given that its 
conditioning variables are at their means, 
J.lj = E {Xj I Pcm= J.ICO)}, 
_and its conditional variance, given that its conditioning variables are at their means, 
vj = Var {Xj 1 Ycm= J.lC(j)}. 
For each conditioning variable ke C(j), we also need the linear coefficient, 
bkj = aldyk E { xj 1 Xcm = x em} . 
evaluated at xcm= J.L C(j)· 
All of the algorithms have been worked out to manipulate models in this form. 
They allow one to transform a problem from this representation to the conventional mean 
vector and covariance matrix form and back again. The different influence diagram 
operations of expectation and reversal can be simply performed on the problem in the 
Gaussian influence diagram. 
The real advantage of using the influence diagram for the normal model is in the 
assessment of a multivariate normal model. Unlike the assessment of a covariance matrix, 
conditional independence simplifies the process and the numbers have a physical 
interpretation. Maintaining a valid {positive semi-definite) covariance structure is assured 
by requiring the conditional variances to be nonnegative. Singular (or almost singular) 
covariance matrices are dealt with easily in the influence diagram, whereas they might 
present problems with more conventional approaches. 
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Methodology 
In this section we discuss the assumptions made to approximate the assessment 
model by a normal influence diagram. Every variable in the model, including experimental 
data, must somehow be transformed into a normal random variable. If the relationships 
among these transformed variables are nonlinear, then some linear approximation must 
be used. Our method then interates, to improve this approximation. 
The types of variables needed for the analysis of t-PA are probabilities, the 
difference between probabilities, and the results of randomized controlled trials (RCT). 
We want a monotone transformation for each variable, such that the errors can all be 
reasonably considered Gaussian. We used the log-odds transformation for the 
probabilities, log(p/(1-p) ), which has often been used for this purpose. (When a prior 
distribution was needed for such a variable, the Jeffreys (1961) prior was used for the 
log-odds, normal with mean 0 and variance�-) A similar transformation, log((1+p) /(1-p) ) 
was used for the difference of probabilities. An RCT transformed variable, Y, with (log­
odds of) success probability given by variable X, waassumed to be normally distributed 
with mean X and variance given by �(s,2) + �(n-s,2) where � is the Riemann zeta 
function, and s successes were observed out of n trials. This approximation leads to 
results similar to the beta-binomial conjugate distribution model, after the variable is 
instantiated with a value of w(s)-w(n-s), where 'JI is the Euler psi or digamma function. 
The linear approximation to nonlinear relationships were obtained by a simple 
heuristic. There were two functions for which it was needed. First, it was used to define 
the difference between probability of mortality for t-PA and CC. While the difference 
would be linear if the variables were the probabilities, it is nonlinear in terms of the log­
odds transformations. The other function was the chaining relationship, expressing the 
probability of mortality in terms of probabilities of reperfusion and mortality given 
reperfusion or not reperfusion: 
Pr{ Mortality } = Pr { Mortality 1 Reperfusion } · Pr { Reperfusion } 
+ Pr { Mortality 1 Not Reperfusion } · (1 - Pr { Reperfusion }). 
To approximate the expected value of this function, it was evaluated at the expected 
value of its arguments, which were themselves approximated by the inverse transforms of 
their means. The gradient of this function was evaluated at the same point. 
This linear approximation is obviously a weak point in the model. However, its 
accuracy was improved through iteration. The linear approximation in the first iteration 
used the prior distribution for each mean (before instantiation). After each iteration the 
linear approximation was recalculated using the gradient at the posterior mean instead of 
the prior. In this and other examples, this technique has converged quickly. 
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Example of t-PA Analysis with Heuristic Method 
The t-PA assessment is represented by the influence diagram in Figure 2. In the 
figure, the ACT data to be instantiated are indicated by shading. These data are given in 
the table below: 
Study Treatment Outcome Successes Trials 
TIMI (1985) t-PA Reperfusion 78 118 
IVSK Reperfusion 44 122 
Collen et al (1984) t-PA Reperfusion 25 33 
cc Reperfusion 25 33 
Yusuf et al (1985) IVSK Mortality 412 2672 
cc Mortality 501 2612 
Kennedy et al (1985) TA Mortality 1 Reperfusion 5 93 
TA Mortality 1 No Reperfusion 6 41 
cc Mortality 1 Reperfusion 0 14 
cc Mortality 1 No Reperfusion 17 102 
Figure 2. Influence Diagram for the Analysis of t-PA. 
The experiments to be instantiated are shaded. 
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A simple test system was written for this problem using ExperCommonLisp on the 
Macintosh computer. It takes one simple function call for each variable defined in the 
model. The first six iterations from the test system are: 
Pr{Mort.lt-PA}-Pr{Mort.ICC} Pr{Mort.ICC} Pr{Mort.lt-PA} Pr{Mort.IIVSK} 
-0.070061 0.1916976 0.1519070 0.1519070 
-0.088682 0.1911351 0.1087691 0.1530587 
-0.087049 0.1913679 0.1044005 0.1530891 
-0.087141 0.1913791 0.1042373 0.1530686 
-0.087146 0.1913792 0.1042328 0.1530680 
-0.087147 0.1913797 0.1042325 0.1530680 
This problem takes minutes to enter into the computer and takes under two 
minutes to solve. The more polished and friendly PC version takes a couple of hours to 
enter the problem and solve it. The answer from that system is that the difference has a 
mean of -8% (a decrease in the probability of mortality of 8%) with a standard deviation of 
about 2.5%. This compares well with the quick and easy approximation of -8.7% with a 
standard deviation of 1. 7%. 
Conclusions 
Much work remains to be done with this heuristic approach. The techniques 
need to be extended to include other forms of data and relationships found in medical 
technology assessment. These include: 
• other types of experiments, such as retrospective case control trials, 
• models of systematic errors in the observation of outcomes, or dilution 
and contamination (patients refusing or seeking treatment despite their 
assignment to a treatment or control group) , and 
• adjustments, to account for differences between studies, such as 
dosages and patient characteristics. 
We also need to refine and validate the approximations taken. In particular, we will 
be working on the step in which the expected value of a transformed variable is 
approximated by a linear function of other transformed variables. The validation work can 
proceed in two directions: comparing the results of this model with other assessments 
performed with the PC system and using other approaches to approximate non-Gaussian 
multivariate models. 
An interesting extension of this approach would be the development of an expert 
system interface to build the influence diagram model. Such a system would need a 
knowledge base about the construction of these types of statistical models. If 
successful, it would further reduce the statistical burden on the medical researcher, and 
permit medical analysts who are less mathematically sophisticated to make full use of the 
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system. . 
Finally, the results and techniques in this paper extend beyond medical 
technology assessment to many problems in which experimental results are being 
integrated to form probability distributions for population parameters. The problems we 
have had to overcome in organizing and analyzing our assessments are endemic to all 
such learning systems. The task of gathering, interpreting, and distilling the results from 
experimental studies is the one task that can never be automated. Our goal is to provide 
an expert system environment to complete the analysis once those data have been 
prepared. 
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